The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
Open accessAbstract
Hypertriglyceridemia is a risk factor for atherosclerotic coronary heart disease. Very high triglyceride (TG) levels (> or =500 mg/dl [5.65 mmol/l]) increase the risk of pancreatitis. One therapeutic option to lower TG levels is omega-3 fatty acids, which are derived from the oil of fish and other seafood. The American Heart Association has acknowledged that fish oils may decrease dysrhythmias, decrease sudden death, decrease the rate of atherosclerosis and slightly lower blood pressure, and has recommended fish consumption or fish oil supplementation as a therapeutic strategy to reduce cardiovascular disease. A prescription omega-3-acid ethyl esters (P-OM3) preparation has been available in many European nations for at least a decade, and was approved by the US FDA in 2004 to reduce very high TG levels (> or =500 mg/dl [5.65 mmol/l]). Mechanistically, most evidence suggests that omega-3 fatty acids reduce the synthesis and secretion of very-low-density lipoprotein (VLDL) particles, and increase TG removal from VLDL and chylomicron particles through the upregulation of enzymes, such as lipoprotein lipase. Omega-3 fatty acids differ mechanistically from other lipid-altering drugs, which helps to explain why therapies such as P-OM3 have complementary mechanisms of action and, thus, complementary lipid benefits when administered with statins. Additional human studies are needed to define more clearly the cellular and molecular basis for the TG-lowering effects of omega-3 fatty acids and their favorable cardiovascular effects, particularly in patients with hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Effects ofn-3 fatty acids on cartilage metabolism
Curtis, C. L., Rees, S., Cramp, J., Flannery, C. R., Hughes, C., Little, C. B., Williams, R., Wilson, C., Dent, C., Harwood, J. L., et al. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2002174 · Cited by 65
RetractedDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610
Global strategy on diet, physical activity and health
Samuelson, G. (2004) · Food & Nutrition Research · doi:10.3402/fnr.v48i2.1503 · Cited by 2,319
(1999) · PubMed · Cited by 2,062
Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases
Simopoulos, A. P. (2002) · Journal of the American College of Nutrition · doi:10.1080/07315724.2002.10719248 · Cited by 2,009
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Self-citationHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Self-citationRajkumar, H., Mahmood, N., Kumar, M., Varikuti, S. R., Challa, H. R., & Myakala, S. P. (2014) · Mediators of Inflammation · doi:10.1155/2014/348959 · Cited by 301
“Therefore in the present study, we compared the effects of probiotics with omega-3 fatty acid, which is well known for its anti-inflammatory properties and cholesterol lowering effect [20].”
BackgroundLipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Siri-Tarino, P. W., Chiu, S., Bergeron, N., & Krauss, R. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034449 · Cited by 268
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263
“Potential mechanisms for the effects of EPA and DHA on Apo B–containing lipoproteins were reviewed by Bays and colleagues.(50) Reductions in TG may result from increased clearance, reduced synthesis, and/or enhanced degradation of fatty acids in the liver.”
BackgroundThe clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
Backes, J., Anzalone, D., Hilleman, D., & Catini, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0286-4 · Cited by 195
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141
“Given that other omega-3 fatty acid therapies of EPA and DHA in hypertriglyceridemic patients may (substantially) increase LDL-C levels [35, 36], the lack of LDL-C increases in MARINE and ANCHOR may be explained by the lack of DHA in IPE.”
BackgroundSelf-citationJayedi, A., & Shab-Bidar, S. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa029 · Cited by 124
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94
Self-citationMaki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Self-citationMaki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.09.001 · Cited by 81
Self-citationKoh, K. K., Quon, M. J., Shin, K.-C., Lim, S., Lee, Y., Sakuma, I., Lee, K., Han, S. H., & Shin, E. K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.018 · Cited by 61
Oh, P. C., Koh, K. K., Sakuma, I., Lim, S., Lee, Y., Lee, S., Lee, K., Han, S. H., & Shin, E. K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.075 · Cited by 54
“Consumption of omega-3 fatty acids causes improvement in many relevant cardiovascular biomarkers including those represented by hypertriglyceridemia [4], vascular dysfunction [5,6], and inflammation [6].”
BackgroundBays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0397 · Cited by 54
“effect is achieved are not completely understood.(19) One potential mechanism involves increased degradation of fatty acids in the liver (through enhancing β-oxidation), which decreases the amount of substrate available for triglyceride synthesis and incorporation into VLDL particles.”
BackgroundInfluentialSelf-citationBallantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.005 · Cited by 52
Self-citationBallantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47
Self-citationZarezadeh, M., Faghfouri, A. H., Radkhah, N., Foroumandi, E., Khorshidi, M., Rasouli, A., Zarei, M., Mohammadzadeh Honarvar, N., Hazhir Karzar, N., & Ebrahimi Mamaghani, M. (2021) · Phytotherapy Research · doi:10.1002/ptr.6834 · Cited by 46
Tatsuno, I., Saito, Y., Kudou, K., & Ootake, J. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.01.006 · Cited by 42
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100148 · Cited by 33
Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181b0cf71 · Cited by 32
“Omega-3 fatty acids and fibrates significantly reduce TG levels by both limiting the secretion of VLDL and enhancing the conversion of VLDL to LDL particles.(6,7) Despite some similarity in their mechanism of action, the combination of fibrates and omega-3 fatty acids is often used to lower TG levels in subjects who a…”
BackgroundSelf-citationMaki, K. C., Bobotas, G., Dicklin, M. R., Huebner, M., & Keane, W. F. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.10.010 · Cited by 20
(2012) · PubMed · Cited by 19
Koh, K. K., Oh, P. C., Sakuma, I., Lee, Y., Han, S. H., & Shin, E. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.038 · Cited by 11
“Meanwhile, consumption of n−3 FA causes improvement in many relevant cardiovascular biomarkers including those represented by hypertriglyceridemia [11], vascular dysfunction and inflammation [12].”
Background
Metadata
- Authors
- Bays, H. E., Tighe, A. P., Sadovsky, R., & Davidson, M. H.
- Venue
- Expert Review of Cardiovascular Therapy
- Publisher
- Informa UK Limited
- Published
- 2008-03
- Volume
- 6
- Issue
- 3
- Pages
- 391-409
- ISSN
- 1477-9072 (ISSN-L)
- 1744-8344
- OpenAlex
- W1998826672
- Cited by
- 265
- References
- 191
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.